文献速递免疫规划传染病防控与疫情报告

无针皮内接种重组PRRSV载体CSFV E2疫苗增强仔猪体液免疫与生长性能

Needle-free intradermal delivery of a recombinant PRRSV-vectored CSFV E2 vaccine enhances humoral immunity and growth performance in piglets.
PubMed 文献 · Vaccine · 2026-01-20

两种接种途径均于接种后14天诱导PRRSV与CSFV血清阳转,皮内组两种抗原抗体水平显著更高(p<0.05)。皮内组未检出PRRSV RNA、无发热及病变,平均日增重显著优于肌内注射组。

要点

  • 无针皮内接种rPRRSV-E2疫苗在14 dpv即诱导PRRSV与CSFV血清阳转。
  • 皮内组对两种抗原的抗体水平显著高于肌内注射组(p<0.05)。
  • 皮内组未检出PRRSV RNA,无发热及大体/组织病变,平均日增重优于肌内注射。

核心结论

  • 无针皮内接种rPRRSV-E2疫苗可诱导仔猪对PRRSV和CSFV的强体液免疫,病原清除能力与常规注射相当,并改善生长性能。

研究设计与样本

  • 接种后追踪临床症状、生长和直肠温度至63 dpv,用ELISA检测PRRSV/CSFV抗体,RT-qPCR检测血清、拭子和组织中的病毒RNA,63 dpv进行大体与组织病理学检查。

主要发现

  • 两种接种途径均于14 dpv诱导PRRSV和CSFV血清阳转,皮内注射组对两种抗原的抗体水平显著更高(p<0.05)。
  • 两个接种组样本中均未检出PRRSV RNA。
  • 与肌内注射相比,皮内注射显著提高平均日增重,且未引起发热或明显临床症状,无大体或镜下病变,与对照组相比大体病理无差异。

临床怎么用

  • 无针皮内接种可作为猪群PRRSV与CSFV综合防控的可行、符合动物福利的免疫策略,适用于生物安全驱动和高通量疫苗接种程序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and Classical Swine Fever Virus (CSFV) remain among the most economically devastating pathogens of swine worldwide. Needle-free intradermal vaccination has emerged as a promising alternative to conventional injection, potentially improving animal welfare, biosecurity, and antigen delivery efficiency within high-density swine production systems. A recombinant PRRSV-vectored live vaccine expressing the CSFV E2 protein (rPRRSV-E2) was evaluated in fifteen 30-day-old healthy piglets. Animals were randomly assigned to three groups: intramuscular injection of rPRRSV-E2 vaccine(needle-based rPRRSV-E2 immunization), intradermal injection of rPRRSV-E2 vaccine (needle-free rPRRSV-E2 immunization), or mock control. Piglets were tracked for clinical signs, growth, and rectal temperature to 63 dpv (Days Post Vaccination). PRRSV/CSFV antibodies were assayed by Enzyme linked immunosorbent assay (ELISA); viral RNA in serum, swabs, and tissues by RT-qPCR. Gross and histopathology were done at 63 dpv. Both vaccination routes induced seroconversion to PRRSV and CSFV by 14 dpv, with the intradermal injection group exhibiting significantly higher antibody level for both antigens (*p < 0.05). No PRRSV RNA was detected in samples from either vaccinated group. Compared to intramuscular injection, intradermal injection significantly improved the average daily weight gain, while causing no fever or notable clinical symptoms, no macroscopic or microscopic lesions, and no differences in gross pathology were noted relative to controls. Intradermal injection of rPRRSV-E2 vaccine elicited robust humoral responses against PRRSV and CSFV, matched pathogen clearance capacity of conventional injection, improved growth performance, and reduced the need for invasive handling. These findings support intradermal injection as a viable, welfare-oriented strategy for integrated control of PRRSV and CSFV in swine herds, with potential application in biosecurity-driven and high-throughput vaccination programs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shuai W, Sun Q, Li J, et al. Needle-free intradermal delivery of a recombinant PRRSV-vectored CSFV E2 vaccine enhances humoral immunity and growth performance in piglets. Vaccine. 2026. PMID: 41564839. doi:10.1016/j.vaccine.2026.128247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。